Teligent Net Income 2012-2021 | TLGT
Teligent net income from 2012 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
|
Teligent Annual Net Income (Millions of US $) |
|
|---|---|
| 2020 | $-122 |
| 2019 | $-25 |
| 2018 | $-36 |
| 2017 | $-15 |
| 2016 | $-12 |
| 2015 | $7 |
| 2014 | $5 |
| 2013 | $-1 |
| 2012 | $-4 |
| 2011 | $-3 |
|
Teligent Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2021-06-30 | $-13 |
| 2021-03-31 | $2 |
| 2020-12-31 | $-80 |
| 2020-09-30 | $-1 |
| 2020-06-30 | $-14 |
| 2020-03-31 | $-27 |
| 2019-12-31 | $-5 |
| 2019-09-30 | $-7 |
| 2019-06-30 | $-4 |
| 2019-03-31 | $-9 |
| 2018-12-31 | $-14 |
| 2018-09-30 | $-4 |
| 2018-06-30 | $-13 |
| 2018-03-31 | $-5 |
| 2017-12-31 | $-6 |
| 2017-09-30 | $-9 |
| 2017-06-30 | $-1 |
| 2017-03-31 | $1 |
| 2016-12-31 | $-5 |
| 2016-09-30 | $-3 |
| 2016-06-30 | $-3 |
| 2016-03-31 | $-1 |
| 2015-12-31 | $-6 |
| 2015-09-30 | $-3 |
| 2015-06-30 | $9 |
| 2015-03-31 | $7 |
| 2014-12-31 | $6 |
| 2014-09-30 | $0 |
| 2014-06-30 | $0 |
| 2014-03-31 | $0 |
| 2013-12-31 | $-1 |
| 2013-09-30 | $0 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-12-31 | $-1 |
| 2012-09-30 | $-1 |
| 2012-06-30 | $-1 |
| 2012-03-31 | $-1 |
| 2011-12-31 | $-1 |
| 2011-09-30 | $0 |
| 2011-06-30 | $-1 |
| 2011-03-31 | $-1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $39.071B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.055B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |